Read by QxMD icon Read

hcv reinfection

Giuliano Ramadori, Patrizia Bosio, Federico Moriconi, Ihtzaz A Malik
BACKGROUND: After orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), recurrent HCC mostly develops within 2 years. All cases of de novo HCC described so far occurred later than 2 years after OLT. Prevention of post-transplantation HCC has usually been tried to achieve by curing or controlling recurrent liver disease. This has been rationale for treatment with interferon (IFN)/ribavirin of HCV-recurrence in patients after OLT, transplanted for advanced HCV-induced liver disease and/or HCC...
March 6, 2018: BMC Cancer
Ralf Bartenschlager, Thomas F Baumert, Jens Bukh, Michael Houghton, Stanley M Lemon, Brett D Lindenbach, Volker Lohmann, Darius Moradpour, Thomas Pietschmann, Charles M Rice, Robert Thimme, Takaji Wakita
The development and clinical implementation of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C. Infection with any viral genotype can now be eliminated in more than 95% of patients with short courses of all-oral, well-tolerated drugs, even in those with advanced liver disease and liver transplant recipients. DAAs have proven so successful that some now consider hepatitis C virus (HCV) amenable to eradication, and continued research on the virus of little remaining medical relevance...
February 22, 2018: Virus Research
Pierre Pradat, Thomas Huleux, François Raffi, Pierre Delobel, Marc-Antoine Valantin, Isabelle Poizot-Martin, Pascal Pugliese, Jacques Reynes, David Rey, Bruno Hoen, André Cabie, Firouzé Bani-Sadr, Antoine Cheret, Claudine Duvivier, Christine Jacomet, Anne Fresard, Laurent Hustache-Mathieu, Laurent Cotte
OBJECTIVE: High hepatitis C virus (HCV) treatment uptake combined with effective direct-acting antiviral-based regimens resulted in a dramatic decline of HCV infection in French people living with HIV (PLWH). We assessed the yearly incidence of new HCV infection in PLWH enrolled in the large French Dat'AIDS cohort from 2012 to 2016 with a specific focus on MSM. METHODS: The incidence of new HCV infection was determined yearly in HCV-negative PLWH with serological follow-up during 2012-2016...
February 12, 2018: AIDS
Mitchell L Shiffman
The epidemic of hepatitis C virus (HCV) began in the 1960s when transmission was primarily the result of blood transfusions. By 1990, when HCV was identified and a serologic test for screening donated blood was implemented, 123 million persons had already become infected worldwide and HCV was the most common cause of cirrhosis, hepatocellular carcinoma and the most common indication for liver transplantation. Approximately 75% of persons with HCV are "baby boomers" born between the years 1945 and 1965...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
S Miuma, H Miyaaki, Y Miyazoe, T Suehiro, R Sasaki, H Shibata, N Taura, K Nakao
Sofosbuvir plus ledipasvir (SOF-LDV) combination therapy is a promising therapy for post-transplant hepatitis C virus (HCV) reinfection. It is known that gastric pH elevation induces lower absorption of ledipasvir; therefore, the use of proton pump inhibitors (PPIs) should be considered regarding dose reduction after SOF-LDV therapy induction. Here, we report two patients who developed duodenal ulcers due to the discontinuation of PPIs after the induction of SOF-LDV therapy for post-transplant HCV reinfection...
January 2018: Transplantation Proceedings
Vicente Soriano, Benjamin Young, Nancy Reau
The International Conference on Viral Hepatitis 2017 brought exciting news on the treatment of viral hepatitis. The most recent estimates of the burden for hepatitis B virus and hepatitis C virus (HCV) infections were presented. The current gaps and prospects for regional and global eradication of viral hepatitis were discussed on the light of the WHO roadmap until 2030. Debates focused on hepatitis C and expectations using the new approved HCV pan-genotypic, once daily, oral direct-acting antivirals (DAAs), glecaprevir-pibrentasvir, and sofosbuvir-velpatasvir-voxilaprevir...
January 25, 2018: AIDS Reviews
Oluwaseun Falade-Nwulia, Mark S Sulkowski, Alana Merkow, Carl Latkin, Shruti H Mehta
The availability of effective, simple, well tolerated oral direct acting antiviral (DAA) hepatitis C regimens have raised optimism for HCV elimination at the population level. HCV reinfection in key populations such as people who inject drugs (PWID) and HIV-infected men who have sex with men (MSM) however threatens the achievement of this goal both from a patient, provider and population perspective. The goal of this review is to synthesize our current understanding of estimated rates and factors associated with HCV reinfection...
January 6, 2018: Journal of Viral Hepatitis
Angelika Schütz, Stephan Moser, Cornelia Schwanke, Raphael Schubert, Julian Luhn, Enisa Gutic, Tobias Lang, Michael Schleicher, Hans Haltmayer, Michael Gschwantler
An important subgroup of people who inject drugs (PWID) receiving opioid agonist therapy (OAT), cannot be treated in the setting of a hepatology center and would not regularly ingest their medication when handed to them for self-administration. Our hypothesis was that chronic hepatitis C in these patients could be ideally managed if modern, interferon-free regimens were administered together with OAT under direct observation of a physician or nurse at a low-threshold facility. In this open-label, non-interventional, proof-of-concept study (ClinicalTrials...
January 5, 2018: Journal of Viral Hepatitis
Jason Grebely, Olav Dalgard, Brian Conway, Evan B Cunningham, Philip Bruggmann, Behzad Hajarizadeh, Janaki Amin, Julie Bruneau, Margaret Hellard, Alain H Litwin, Philippa Marks, Sophie Quiene, Sharmila Siriragavan, Tanya L Applegate, Tracy Swan, Jude Byrne, Melanie Lacalamita, Adrian Dunlop, Gail V Matthews, Jeff Powis, David Shaw, Maria Christine Thurnheer, Martin Weltman, Ian Kronborg, Curtis Cooper, Jordan J Feld, Chris Fraser, John F Dillon, Phillip Read, Ed Gane, Gregory J Dore
BACKGROUND: Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID. This study aimed to evaluate the efficacy of sofosbuvir and velpatasvir therapy in people with chronic HCV infection and recent injection drug use. METHODS: In this open-label, single-arm phase 4 trial (SIMPLIFY), we recruited participants with recent injection drug use (past 6 months) and chronic HCV genotype 1-6 infection from seven countries (19 sites)...
January 5, 2018: Lancet. Gastroenterology & Hepatology
Victor Virlogeux, Fabien Zoulim, Pascal Pugliese, Isabelle Poizot-Martin, Marc-Antoine Valantin, Lise Cuzin, Jacques Reynes, Eric Billaud, Thomas Huleux, Firouze Bani-Sadr, David Rey, Anne Frésard, Christine Jacomet, Claudine Duvivier, Antoine Cheret, Laurent Hustache-Mathieu, Bruno Hoen, André Cabié, Laurent Cotte
BACKGROUND: HCV treatment uptake has drastically increased in HIV-HCV coinfected patients in France since direct-acting antiviral (DAA) treatment approval, resulting in HCV cure in 63% of all HIV-HCV patients by the end of 2015. We investigated the impact of scaling-up DAA on HCV prevalence in the whole HIV population and in various risk groups over the next 10 years in France using a transmission dynamic compartmental model. METHODS: The model was based on epidemiological data from the French Dat'AIDS cohort...
December 18, 2017: BMC Medicine
Tamar Kikvidze, Niklas Luhmann, Elisabeth Avril, Maia Butsashvili, Konstantine Labartkava, Aurélie Etienne, Diane Le Pluart, Ina Inaridze, Ana Gamezardashvili, David Kharshiladze, Julie Bouscaillou
No abstract text is available yet for this article.
February 2018: International Journal on Drug Policy
Michael Doyle, Lisa Maher, Simon Graham, Handan Wand, Jenny Iversen
OBJECTIVE: To examine factors associated with hepatitis C virus (HCV) infection among a national sample of Indigenous and non-Indigenous people who inject drugs (PWID) in Australia. METHODS: Respondents were recruited from Australia's Needle Syringe Program Survey; an annual bio-behavioural surveillance project that monitors HCV antibody prevalence among PWID. Data from 2006-2015 were de-duplicated to retain only one record where individuals participated in >1 survey round...
November 22, 2017: Australian and New Zealand Journal of Public Health
Giuseppe Bruno, Annalisa Saracino
Although HIV/HCV co-infected individuals were historically considered a "difficult to treat" population in the era of Interferon (IFN)-based anti-HCV treatment, the introduction of direct-acting antivirals, characterized by excellent efficacy and good safety profile, has widely revolutionized the HCV treatment scenario. Recent real life studies reported excellent sustained virological response rates in HIV/HCV co-infected subjects, thus confirming data obtained in randomized clinical trials. However, certain issues have recently emerged in this population...
November 8, 2017: Current HIV Research
Renata Wieczorek-Godlewska, Rafał Płoski, Agnieszka Perkowska-Ptasińska, Olga Tronina, Anna Sadowska, Marek Pacholczyk, Wojciech Lisik, Magdalena Durlik
AIM OF THE STUDY: Aim of the study was to assess the impact of the recipient and donor interferon lambda-3 (IFNL3) single-nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 on the course of hepatitis C virus (HCV) reinfection following liver transplantation. MATERIAL AND METHODS: The study involved 141 subjects after liver transplantation for HCV-induced cirrhosis, performed between 2000 and 2015. It assessed the impact of both SNPs on the outcomes of interferon/ribavirin (IFN/RBV) treatment following transplantation, HCV viral load, laboratory test results, histological lesions in the liver graft, the risk of acute rejection, and the development of hepatocellular carcinoma (HCC) in patient's own liver...
September 2017: Clinical and Experimental Hepatology
Sabrina A Assoumou, Abriana Tasillo, Jared A Leff, Bruce R Schackman, Mari-Lynn Drainoni, C Robert Horsburgh, M Anita Barry, Craig Regis, Arthur Y Kim, Alison Marshall, Sheel Saxena, Peter C Smith, Benjamin P Linas
Background: High hepatitis C virus (HCV) rates have been reported in young people who inject drugs (PWID). We evaluated the clinical benefit and cost-effectiveness of testing among youth seen in communities with a high overall number of reported HCV cases. Methods: We developed a decision analytic model to project quality-adjusted life years (QALYs), lifetime costs (2016 US $), and incremental cost-effectiveness ratios (ICER) associated with nine strategies for one-time testing among 15 to 30-year-olds seen at urban community health centers...
September 9, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Mohamed Abdel-Wahab, Ehab E Abdel-Khalek, Abdel-Hady El-Gilany, Amr M Yassen, Mohamed Al-Shobari, Usama Shiha, Mahmoud Ali, Mohamed Sadani, Tarek Salah, Ahmad M Sultan, Ahmed N Elghawalby, Mohamed Elmorshedi, Al-Refaey K Al-Refaey, Usama Abdalla
BACKGROUND AND STUDY AIMS: Hepatitis C virus (HCV)-related cirrhosis is the leading cause of liver transplantation (LT). All patients who undergo LT with detectable serum HCV-RNA experience graft reinfection, which is the most frequent cause of graft loss and death in these patients. We estimated the rate of HCV recurrence and evaluated the current therapeutic regimens. PATIENTS AND METHODS: The records of consecutive 325 living donor LT (LDLT) surgeries performed between May 2004 and August 2014 were retrospectively analysed; 207 of them were followed-up throughout the study...
September 2017: Arab Journal of Gastroenterology: the Official Publication of the Pan-Arab Association of Gastroenterology
Nazrul Islam, Mel Krajden, Jean Shoveller, Paul Gustafson, Mark Gilbert, Jason Wong, Mark W Tyndall, Naveed Zafar Janjua
While about a quarter of individuals clear their primary hepatitis C (HCV) infections spontaneously, clearance (spontaneous or treatment-induced) does not confer sterilizing immunity against a future infection. Since successful treatment does not prevent future infections either, an effective vaccine is highly desirable in preventing HCV (re)infection. However, development of an effective vaccine has been complicated by the diversity of HCV genotypes, and complexities in HCV immunological responses. Smaller studies on humans and chimpanzees reported seemingly opposing results regarding cross-neutralizing antibodies...
September 26, 2017: Scientific Reports
Jürgen K Rockstroh, Chloe Orkin, Rolando M Viani, David Wyles, Anne F Luetkemeyer, Adriano Lazzarin, Ruth Soto-Malave, Mark R Nelson, Sanjay R Bhagani, Hartwig H F Klinker, Giuliano Rizzardini, Pierre-Marie Girard, Cristina Tural, Nancy S Shulman, Niloufar Mobashery, Yiran B Hu, Linda M Fredrick, Tami Pilot-Matias, Roger Trinh, Edward Gane
BACKGROUND: Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for HCV genotype 1, and OBV/PTV/r + RBV for HCV genotype 4, in human immunodeficiency virus (HIV)-1 coinfected patients with or without compensated cirrhosis. METHODS: TURQUOISE-I, Part 2 is a phase 3 multicenter study...
2017: Open Forum Infectious Diseases
K Rajender Reddy, Stanislas Pol, Paul J Thuluvath, Hiromitsu Kumada, Joji Toyota, Kazuaki Chayama, James Levin, Eric J Lawitz, Adrian Gadano, Wayne Ghesquiere, Guido Gerken, Maurizia R Brunetto, Cheng-Yuan Peng, Marcelo Silva, Simone I Strasser, Jeong Heo, Fiona McPhee, Zhaohui Liu, Rong Yang, Misti Linaberry, Stephanie Noviello
BACKGROUND & AIMS: Daclatasvir has achieved high sustained virologic response (SVR) rates in diverse hepatitis C virus (HCV) populations. This study evaluated the long-term efficacy and safety of daclatasvir-based regimens administered during clinical studies. METHODS: Patients enrolled within 6 months of parent study completion or protocol availability at the study sites. The primary objective was durability of SVR at follow-up Week 12 (SVR12). Secondary objectives included analysing HCV sequences in non-responders or responders who relapsed, and characterization of liver disease progression...
September 21, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
H-T Liao, P Tan, J-W Huang, K-F Yuan
INTRODUCTION: Studies focusing on the efficacy and safety of ledipasvir (LDV) + sofosbuvir (SOF) therapy in liver transplant (LT) recipients with hepatitis C virus (HCV) recurrence are still limited. Therefore, the aim of our work was to perform a systematic review and meta-analysis to evaluate outcome data of LDV + SOF therapy in LT recipients. METHODS: Multiple databases were systematically searched for eligible studies. We included studies reporting sustained virological response 12 weeks after treatment (SVR12) and treatment-related adverse events (AEs) in LT recipients treated with LDV + SOF ± ribavirin (RBV) for HCV recurrence...
October 2017: Transplantation Proceedings
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"